| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 6
| Issue : 3 | Page : 106-110 |
|
|
Sensitive allele specific oligonucleotide-polymerase chain reaction in detection of preexisting mutations in imatinib-resistant chronic myelogenous leukemia patients: A retrospective analysis
Mukul Arvind Gharote1, Harsha Panchal1, Apurva Patel1, Sonia Parikh1, Rakesh Rawal2, Krupa Shah2, Asha S Anand1
1 Department of Medical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
2 Department of Molecular Biology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
Correspondence Address:
Mukul Arvind Gharote
D-403, Vasant Vihar, Phase 2, Airport Road, Shahibaug, Ahmedabad - 380 014, Gujarat
India
 Source of Support: Nil., Conflict of Interest: There are no conflicts of interest.  | Check |
DOI: 10.4103/1658-5127.165648
|
|
|
Introduction: Pre-existing BCR-ABL kinase domain mutation leads to Imatinib resistance. Methods: Retrospective analysis of 50 patients of Imatinib resistance was done in GCRI, from January 2014 till May 2014. Allelle Specific Oligonucleotide–Polymerase Chain Reaction (ASO-PCR) was performed on Genomic DNA, of peripheral blood mononuclear cells (PBMCs). Results: 47 (94%) were in Chronic phase, 2 (4%) in accelerated phase, 1 (2%) in blastic crisis. Median duration of Imatinib was 48 months. 43/50 had one or more than 1 mutation, T315I mutation in 5 (10%) patients, M351T in 32% (16/50) and F311L in 8. Conclusion: We report low cytogenetic response (25%) and durability of response to 600 mg of Imatinib, even in M351T mutation. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
